Autism Therapy Market would rise to USD 3.42 billion by 2030

The growing incidence of autism and pervasive developmental disorder (PDD) is essential to escalate market growth. Huge research studies performed by organizations to assess the safety and efficiency of drugs in patients with ASD are anticipated to boost market growth. The stimulants segment dominated the market with a huge revenue share due to the wide availability and ease of accessibility of drugs to patients.

Data Bridge Market Research analyses that the autism therapy market, which was USD 2.05 billion in 2022, would rise to USD 3.42 billion by 2030 and is expected to undergo a CAGR of 6.60% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get More Info: https://www.databridgemarketresearch.com/reports/global-autism-therapy-market

Autism therapies are the type of therapies that are applied in autistic children or adults to improve or enhance their condition. Different therapies include speech-language therapy, behavior therapy, play-based therapy, occupational therapy, physical therapy, and nutritional therapy. This neurological disorder is related to several disabilities, such as challenges with the individual's behavior or lack of social skills. The diagnosis of autism can be made from a very early age, but the cause is still unknown.

Recent Development

In 2022, Bened Life launched the first gut-brain medical probiotic named Neuralli. Neuralli is designed to raise awareness about mental health and support neurological conditions including but not limited to Parkinson's disease (P.D.) and autism spectrum disorder (ASD).
In 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), stated the highly successful completion of the phase 1b trials for its lead drug candidate STP1.

Some of the major players operating in the autism therapy market are:

Pfizer Inc. (U.S.)
Lilly (U.S.)
Abbvie, Inc (U.S.)
Merck & Co., Inc (U.S.).
Teva Pharmaceutical Industries Ltd.(Israel)
Novartis AG (Switzerland)
Johnson & Johnson Services, Inc (U.S.).
Hopebridge, LLC (U.S.)
Bristol-Myers Squibb Company (U.S.)
Otsuka America Pharmaceutical, Inc (Japan)
Curemark, LLC (U.S.).
Sosei Group Corporation (Japan)
Sun Pharmaceutical Industries Ltd.(India)
Mylan N.V. (U.S.).
Endo International plc (Ireland)

More Links:

https://dbmr12232.blogspot.com/2023/06/healthcare-distribution-market-industry_9.html

https://dbmr12232.blogspot.com/2023/06/airway-stent-lung-stent-market-industry_9.html

https://dbmr12232.blogspot.com/2023/06/autoimmune-treatment-market-trends_9.html

https://dbmr12232.blogspot.com/2023/06/genomics-market-trends-drivers-and_9.html

https://dbmr12232.blogspot.com/2023/06/pediatric-interventional-cardiology_9.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.